Immunological effectiveness of mass hepatitis B vaccination

Objective. To evaluate the immunological effectiveness of hepatitis B (HB) vaccination in the population of certain regions of Russia, including those within the Health project. Materials and methods. A total of 803 sera from adults vaccinated against hepatitis B with the Engerix-B vaccine according to the standard immunization schedule (0-1-6 months) were examined in 4 subjects of the Russian Federation (Moscow Region, Sverdlovsk Region, Perm Territory, and Moscow). Blood samples were taken at 3-6 and 7-12 months and 1-2, 3-5, 6-7, and 8-12 years after completing a full HB vaccine series. Hepatitis B markers (HBsAg, anti-HBs, anti-HBcor overall and class IgM) were quantified in the vaccinated by chemiluminescence assay on an automated ARCHITECT immunochemical analyzer using Architect test kits (Abbott Laboratories Diagnostics, USA). The serum concentration of 10 mIU/ml and higher was considered as a seroprotective level of specific antibodies. The results were processed using modern statistical methods. Results. The protective concentrations of specific antibodies were found in the blood of 88.23 ± 8.06% of cases at 3-6 months after completing a full HB vaccine series and persisted in 71.26 ± 4.56% within 8-12 years. At 3-6 months after completion of a full vaccine series, the proportion of individuals with a protective HBV antibody titer in the age groups 20-39 and 40-59 years had no significant differences and accounted for 90.0 ± 10.0% and 89.4 7 ± 7.23%, respectively. At 6-7 years after vaccination, the proportion of the individuals seropositive for HB virus in the age groups 20-39 and 40-59 years decreased to 72.0 ± 5.18 and 71.79 ± 7.21%, respectively. Conclusion. The results obtained from serological monitoring confirmed the high immunological effectiveness of hepatitis B vaccination in the population in some regions of Russia.

hepatitis B, vaccination, immunological effectiveness